Search

Your search keyword '"Botta L"' showing total 1,015 results
Start Over Author "Botta L"
1,015 results on '"Botta L"'

1. Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030

Author

Crocetti, Emanuele, Mallone, Sandra, Pierannunzio, Daniela, Contiero, Paolo, Tagliabue, Giovanna, Memo, Laura, Manneschi, Gianfranco, Ravaioli, Alessandra, Cuccaro, Francesco, Richiardi, Lorenzo, Casella, Claudia, Anna di Prima, Alessia, Maifredi, Giovanni, Lanzoni, Monica, Cirilli, Claudia, Leite, Silvia, Michiara, Maria, Ferraioli, Serena, Zarcone, Maurizio, Vitale, Maria Francesca, Giacomazzi, Erica, Ghisleni, Silvia, Bisceglia, Isabella, Gentilini, Maria A., Vittadello, Fabio, Spata, Eugenia, Marguati, Stefano, Del Riccio, Luciana, Concas, Elisa, Sessa, Alessandra, Colanino, Antonino Ziino, Prazzoli, Rita, Ferrari, Gianfabrizio, Canu, Luisa, Guzzinati, S., Toffolutti, F., Francisci, S., De Paoli, A., Giudici, F., De Angelis, R., Demuru, E., Botta, L., Tavilla, A., Gatta, G., Capocaccia, R., Zorzi, M., Caldarella, A., Bidoli, E., Falcini, F., Bruni, R., Migliore, E., Puppo, A., Ferrante, M., Gasparotti, C., Gambino, M.L., Carrozzi, G., Bianconi, F., Musolino, A., Cavallo, R., Mazzucco, W., Fusco, M., Ballotari, P., Sampietro, G., Ferretti, S., Mangone, L., Mantovani, W., Mian, M., Cascone, G., Manzoni, F., Galasso, R., Piras, D., Pesce, M.T., Bella, F., Seghini, P., Fanetti, A.C., Pinna, P., Serraino, D., Rossi, S., and Dal Maso, L.

Published
2024
Full Text
View/download PDF

2. Twenty-Minute No-Touch Period Before Controlled DCD Heart Retrieval: Is There Still a Chance for Successful Recovery? The Italian Experience

Author

Gerosa, G., primary, Pradegan, N., additional, Tarzia, V., additional, Lena, T., additional, Zanatta, P., additional, Galeone, A., additional, Gottin, L., additional, Onorati, F., additional, Boffini, M., additional, Zanierato, M., additional, Botta, L., additional, Martin Suarez, S., additional, Feccia, M., additional, Lilla Della Monica, P., additional, Oliveti, A., additional, Pacini, D., additional, Rinaldi, M., additional, Luciani, G.B., additional, and Cardillo, M., additional

Published
2024
Full Text
View/download PDF

7. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study

Author

Hackl, M., Zielonke, N., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Dušek, L., Zvolský, M., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Bouvier, A.M., Faivre, J., Bossard, N., Uhry, Z., Colonna, M., Stabenow, R., Luttmann, S., Eberle, A., Brenner, H., Nennecke, A., Engel, J., Schubert-Fritschle, G., Heidrich, J., Holleczek, B., Katalinic, A., Clough-Gorr, K., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Maso, L. Dal, De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Knijn, A., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Natali, M., Filiberti, R.A., Marani, E., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Traina, A., Staiti, R., Vitale, F., Cusimano, R., Michiara, M., Tumino, R., Falcini, F., Caiazzo, A.L., Maspero, S., Fanetti, A.C., Zanetti, R., Rosso, S., Rugge, M., Tognazzo, S., Pildava, S., Smailyte, G., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Kępska, K., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Antunes, L., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Almar, E., Mateos, A., Lopez de Munain, A., Larrañaga, N., Torrella-Ramos, A., Díaz García, J.M., Jimenez-Chillaron, R., Marcos-Gragera, R., Vilardell, L., Moreno-Iribas, C., Ardanaz, E., Lambe, M., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Damhuis, R., Otter, R., Coleman, M., Allemani, C., Rachet, B., Rashbass, J., Broggio, J., Verne, J., Gavin, A., Fitzpatrick, D., Huws, D.W., White, C., Minicozzi, Pamela, Innos, Kaire, Sánchez, Maria-José, Trama, Annalisa, Walsh, Paul M., Marcos-Gragera, Rafael, Dimitrova, Nadya, Botta, Laura, Visser, Otto, Rossi, Silvia, Tavilla, Andrea, and Sant, Milena

Published
2017
Full Text
View/download PDF

8. Geographical variability in survival of European children with central nervous system tumours

Author

Hackl, M., Zielonke, N., Oberaigner, W., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Storm, H., Engholm, G., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Faivre, J., Bossard, N., Uhry, Z., Colonna, M., Clavel, J., Lacour, B., Desandes, E., Brenner, H., Kaatsch, P., Katalinic, A., Garami, M., Jakab, Z., Comber, H., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Sutera Sardo, A., Mancuso, P., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Zucchetto, A., De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Busco, S., Filiberti, R.A., Marani, E., Ricci, P., Pascucci, C., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Usala, M., Vitale, F., Ravazzolo, B., Michiara, M., Merletti, F., Maule, M., Tumino, R., Mangone, L., Di Felice, E., Falcini, F., Iannelli, A., Sechi, O., Cesaraccio, R., Piffer, S., Madeddu, A., Tisano, F., Maspero, S., Fanetti, A.C., Candela, P., Scuderi, T., Stracci, F., Bianconi, F., Tagliabue, G., Contiero, P., Rugge, M., Guzzinati, S., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Bębenek, M., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Castro, C., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Errezola, M., Bidaurrazaga, J., Vicente Raneda, M., Díaz García, J.M., Marcos-Navarro, A.I., Marcos-Gragera, R., Izquierdo Font, A., Sanchez, M.J., Chang, D.Y.L., Navarro, C., Chirlaque, M.D., Moreno-Iribas, C., Ardanaz, E., Peris-Bonet, R., Pardo Romaguera, E., Galceran, J., Carulla, M., Lambe, M., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Aarts, M., Otter, R., Coleman, M., Allemani, C., Rachet, B., Verne, J., Stiller, C., Gavin, A., Donnelly, C., Brewster, D.H., Sánchez, M.-J., and Rutkowski, S.

Published
2017
Full Text
View/download PDF

9. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

Author

Hackl, M., Zielonke, N., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Dušek, L., Zvolský, M., Storm, H., Engholm, G., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Velten, M., Guizard, A.V., Faivre, J., Woronoff, A.S., Tretarre, B., Bossard, N., Uhry, Z., Colonna, M., Molinié, F., Bara, S., Schvartz, C., Lapôtre-Ledoux, B., Grosclaude, P., Stabenow, R., Luttmann, S., Eberle, A., Brenner, H., Nennecke, A., Engel, J., Schubert-Fritschle, G., Heidrich, J., Holleczek, B., Katalinic, A., Jónasson, J.G., Tryggvadóttir, L., Comber, H., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Sutera Sardo, A., Mazzei, A., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Zucchetto, A., De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Busco, S., Filiberti, R.A., Vercelli, M., Ricci, P., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Usala, M., Vitale, F., Ravazzolo, B., Michiara, M., Tumino, R., Mangone, L., Vicentini, M., Falcini, F., Iannelli, A., Sechi, O., Cesaraccio, R., Piffer, S., Madeddu, A., Tisano, F., Maspero, S., Fanetti, A.C., Zanetti, R., Rosso, S., Candela, P., Scuderi, T., Stracci, F., Rocca, A., Tagliabue, G., Contiero, P., Rugge, M., Tognazzo, S., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Bębenek, M., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Castro, C., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Errezola, M., Bidaurrazaga, J., Díaz García, J.M., Marcos-Navarro, A.I., Marcos-Gragera, R., Izquierdo Font, A., Sanchez, M.J., Molina, E., Navarro, C., Chirlaque, M.D., Moreno-Iribas, C., Ardanaz, E., Galceran, J., Carulla, M., Lambe, M., Khan, S., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Ho, V., Otter, R., Coleman, M., Allemani, C., Rachet, B., Rashbass, J., Broggio, J., Verne, J., Gavin, A., Donnelly, C., Brewster, D.H., Huws, D.W., White, C., Dal Maso, L., Pacini, F., van Dijk, B.A.C., Larrañaga, N., Rubió-Casadevall, J., Kowalska, A., and Virdone, S.

Published
2017
Full Text
View/download PDF

10. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study

Author

Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, Huws, D, Botta L., Gatta G., Capocaccia R., Stiller C., Canete A., Dal Maso L., Innos K., Mihor A., Erdmann F., Spix C., Lacour B., Marcos-Gragera R., Murray D., Rossi S., Hackl M., Van Eycken E., Van Damme N., Valerianova Z., Sekerija M., Scoutellas V., Demetriou A., Dusek L., Krejci D., Storm H., Magi M., Paapsi K., Malila N., Pitkaniemi J., Jooste V., Clavel J., Poulalhon C., Desandes E., Monnereau A., Katalinic A., Petridou E., Markozannes G., Garami M., Birgisson H., Walsh P. M., Mazzoleni G., Vittadello F., Cuccaro F., Galasso R., Sampietro G., Rosso S., Gasparotto C., Maifredi G., Ferrante M., Torrisi A., Sutera Sardo A., Gambino M. L., Lanzoni M., Ballotari P., Giacomazzi E., Ferretti S., Caldarella A., Manneschi G., Sant M., Baili P., Berrino F., Trama A., Lillini R., Bernasconi A., Bonfarnuzzo S., Vener C., Didone F., Lasalvia P., Del Monego G., Buratti L., Serraino D., Taborelli M., De Angelis R., Demuru E., Di Benedetto C., Santaquilani M., Venanzi S., Tallon M., Boni L., Iacovacci S., Russo A. G., Gervasi F., Spagnoli G., Cavalieri d'Oro L., Fusco M., Vitale M. F., Usala M., Vitale F., Michiara M., Chiranda G., Sacerdote C., Maule M., Cascone G., Spata E., Mangone L., Falcini F., Cavallo R., Piras D., Dinaro Y., Castaing M., Fanetti A. C., Minerba S., Candela G., Scuderi T., Rizzello R. V., Stracci F., Tagliabue G., Rugge M., Brustolin A., Pildava S., Smailyte G., Azzopardi M., Johannesen T. B., Didkowska J., Wojciechowska U., Bielska-Lasota M., Pais A., Ferreira A. M., Bento M. J., Miranda A., Safaei Diba C., Zadnik V., Zagar T., Sanchez-Contador Escudero C., Franch Sureda P., Lopez de Munain A., De-La-Cruz M., Rojas M. D., Aleman A., Vizcaino A., Almela F., Sanvisens A., Sanchez M. J., Chirlaque M. D., Sanchez-Gil A., Guevara M., Ardanaz E., Canete-Nieto A., Peris-Bonet R., Galceran J., Carulla M., Kuehni C., Redmond S., Visser O., Karim-Kos H., Stevens S., Gavin A., Morrison D., Huws D. W., Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, Huws, D, Botta L., Gatta G., Capocaccia R., Stiller C., Canete A., Dal Maso L., Innos K., Mihor A., Erdmann F., Spix C., Lacour B., Marcos-Gragera R., Murray D., Rossi S., Hackl M., Van Eycken E., Van Damme N., Valerianova Z., Sekerija M., Scoutellas V., Demetriou A., Dusek L., Krejci D., Storm H., Magi M., Paapsi K., Malila N., Pitkaniemi J., Jooste V., Clavel J., Poulalhon C., Desandes E., Monnereau A., Katalinic A., Petridou E., Markozannes G., Garami M., Birgisson H., Walsh P. M., Mazzoleni G., Vittadello F., Cuccaro F., Galasso R., Sampietro G., Rosso S., Gasparotto C., Maifredi G., Ferrante M., Torrisi A., Sutera Sardo A., Gambino M. L., Lanzoni M., Ballotari P., Giacomazzi E., Ferretti S., Caldarella A., Manneschi G., Sant M., Baili P., Berrino F., Trama A., Lillini R., Bernasconi A., Bonfarnuzzo S., Vener C., Didone F., Lasalvia P., Del Monego G., Buratti L., Serraino D., Taborelli M., De Angelis R., Demuru E., Di Benedetto C., Santaquilani M., Venanzi S., Tallon M., Boni L., Iacovacci S., Russo A. G., Gervasi F., Spagnoli G., Cavalieri d'Oro L., Fusco M., Vitale M. F., Usala M., Vitale F., Michiara M., Chiranda G., Sacerdote C., Maule M., Cascone G., Spata E., Mangone L., Falcini F., Cavallo R., Piras D., Dinaro Y., Castaing M., Fanetti A. C., Minerba S., Candela G., Scuderi T., Rizzello R. V., Stracci F., Tagliabue G., Rugge M., Brustolin A., Pildava S., Smailyte G., Azzopardi M., Johannesen T. B., Didkowska J., Wojciechowska U., Bielska-Lasota M., Pais A., Ferreira A. M., Bento M. J., Miranda A., Safaei Diba C., Zadnik V., Zagar T., Sanchez-Contador Escudero C., Franch Sureda P., Lopez de Munain A., De-La-Cruz M., Rojas M. D., Aleman A., Vizcaino A., Almela F., Sanvisens A., Sanchez M. J., Chirlaque M. D., Sanchez-Gil A., Guevara M., Ardanaz E., Canete-Nieto A., Peris-Bonet R., Galceran J., Carulla M., Kuehni C., Redmond S., Visser O., Karim-Kos H., Stevens S., Gavin A., Morrison D., and Huws D. W.

Abstract

Background: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer. Methods: In this population-based study, we analysed 135 847 children (aged 0–14 years) diagnosed during 2000–13 and followed up to the end of 2014, recruited from 80 population-based cancer registries in 31 European countries. We calculated age-adjusted 5-year survival differences by country and over time using period analysis, for all cancers combined and for major cancer types. We applied a variant of standard mixture cure models for survival data to estimate the cure fraction of patients by childhood cancer and to estimate projected 15-year survival. Findings: 5-year survival for all childhood cancer combined in Europe in 2010–14 was 81% (95% CI 81–82), showing an increase of three percentage points compared with 2004–06. Significant progress over time was observed for almost all cancers. Survival remained stable for osteosarcomas, Ewing sarcoma, Burkitt lymphoma, non-Hodgkin lymphomas, and rhabdomyoscarcomas. For all cancers combined, inequalities still persisted among European countries (with age-adjusted 5-year survival ranging from 71% [95% CI 60–79] to 87% [77–93]). The 15-year survival projection for all patients with childhood cancer diagnosed in 2010–13 was 78%. We estimated the yearly long-term mortality rate due to causes other than the diagnosed cancer to be around 2 per 1000 patients for all childhood cancer combined, but to approach zero for retinoblastoma. The cure fraction for patients with childhood cancer increased over time from 74% (95% CI 73–75) in 1998–

Published
2022

11. The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers.

Author

Trama, A., Licitra, L., Cavalieri, S., Bonfarnuzzo, S., Baili, P., Ciarfella, A., Parente, P., Almadori, G., Ansarin, M., Bacigalupo, A., Baumeister, P., Baujat, B., Bossi, P., Cavalera, E., Cercato, M.C., Dieleman, F., Fakhry, N., Ferraresi, V., Gaino, F., Galizia, D., Halamkova, J., Halme, E., Hardillo, J., Hofauer, B., Kinloch, E., Livi, L., Locati, L.D., Mattheis, S., Mercante, G., Mirabile, A., Molteni, G., Orlandi, E., Persio, R., Sciallero, S., Smeele, L., Tagliabue, M., Valentini, V., Herpen, C.M.L. van, Westphalen, C.Benedikt, Botta, L., Trama, A., Licitra, L., Cavalieri, S., Bonfarnuzzo, S., Baili, P., Ciarfella, A., Parente, P., Almadori, G., Ansarin, M., Bacigalupo, A., Baumeister, P., Baujat, B., Bossi, P., Cavalera, E., Cercato, M.C., Dieleman, F., Fakhry, N., Ferraresi, V., Gaino, F., Galizia, D., Halamkova, J., Halme, E., Hardillo, J., Hofauer, B., Kinloch, E., Livi, L., Locati, L.D., Mattheis, S., Mercante, G., Mirabile, A., Molteni, G., Orlandi, E., Persio, R., Sciallero, S., Smeele, L., Tagliabue, M., Valentini, V., Herpen, C.M.L. van, Westphalen, C.Benedikt, and Botta, L.

Abstract

Item does not contain fulltext, INTRODUCTION: Care for head and neck cancers is complex in particular for the rare ones. Knowledge is limited and histological heterogeneity adds complexity to the rarity. There is a wide consensus that to support clinical research on rare cancer, clinical registries should be developed within networks specializing in rare cancers. In the EU, a unique opportunity is provided by the European Reference Networks (ERN). The ERN EURACAN is dedicated to rare adults solid cancers, here we present the protocol of the EURACAN registry on rare head and neck cancers (ClinicalTrials.gov Identifier: NCT05483374). STUDY DESIGN: Registry-based cohort study including only people with rare head and neck cancers. OBJECTIVES: to help describe the natural history of rare head and neck cancers;to evaluate factors that influence prognosis;to assess treatment effectiveness;to measure indicators of quality of care. METHODS: Settings and participants It is an hospital based registry established in hospitals with expertise in head and neck cancers. Only adult patients with epithelial tumours of nasopharynx; nasal cavity and paranasal sinuses; salivary gland cancer in large and small salivary glands; and middle ear will be included in the registry. This registry won't select a sample of patients. Each patient in the facility who meets the above mentioned inclusion criteria will be followed prospectively and longitudinally with follow-up at cancer progression and / or cancer relapse or patient death. It is a secondary use of data which will be collected from the clinical records. The data collected for the registry will not entail further examinations or admissions to the facility and/or additional appointments to those normally provided for the patient follow-up. Variables Data will be collected on patient characteristics (eg. patient demographics, lifestyle, medical history, health status); exposure data (eg. disease, procedures, treatments of interest) and outcomes (e.g. survival, progressi

Published
2023

12. Developing a comorbidity score in cancer patients using healthcare utilization databases during the COVID-19 pandemic: An experience from Italy

Author

Lasalvia, P, Trama, A, Botta, L, Franchi, M, Bernasconi, A, Lasalvia, P, Trama, A, Botta, L, Franchi, M, and Bernasconi, A

Abstract

Background: A strong relationship has been observed between comorbidities and the risk of severe/fatal COVID-19 manifestations, but no score is available to evaluate their association in cancer patients. To make up for this lacuna, we aimed to develop a comorbidity score for cancer patients, based on the Lombardy Region healthcare databases. Methods: We used hospital discharge records to identify patients with a new diagnosis of solid cancer between February and December 2019; 61 comorbidities were retrieved within 2 years before cancer diagnosis. This cohort was split into training and validation sets. In the training set, we used a LASSO-logistic model to identify comorbidities associated with the risk of developing a severe/fatal form of COVID-19 during the first pandemic wave (March–May 2020). We used a logistic model to estimate comorbidity score weights and then we divided the score into five classes (<=−1, 0, 1, 2–4, >=5). In the validation set, we assessed score performance by areas under the receiver operating characteristic curve (AUC) and calibration plots. We repeated the process on second pandemic wave (October–December 2020) data. Results: We identified 55,425 patients with an incident solid cancer. We selected 21 comorbidities as independent predictors. The first four score classes showed similar probability of experiencing the outcome (0.2% to 0.5%), while the last showed a probability equal to 5.8%. The score performed well in both the first and second pandemic waves: AUC 0.85 and 0.82, respectively. Our results were robust for major cancer sites too (i.e., colorectal, lung, female breast, and prostate). Conclusions: We developed a high performance comorbidity score for cancer patients and COVID-19. Being based on administrative databases, this score will be useful for adjusting for comorbidity confounding in epidemiological studies on COVID-19 and cancer impact.

Published
2023

13. Childhood and Adolescent Central Nervous System Tumours in Spain: Incidence and Survival over 20 Years: A Historical Baseline for Current Assessment

Author

Medicina i Cirurgia, Universitat Rovira i Virgili, Chirlaque MD; Peris-Bonet R; Sánchez A; Cruz O; Marcos-Gragera R; Gutiérrez-Ávila G; Quirós-García JR; Almela-Vich F; López de Munain A; Sánchez MJ; Franch-Sureda P; Ardanaz E; Galceran J; Martos C; Salmerón D; Gatta G; Botta L; Cañete A; The Spanish Childhood Cancer Epidemiology Working Group, Medicina i Cirurgia, Universitat Rovira i Virgili, and Chirlaque MD; Peris-Bonet R; Sánchez A; Cruz O; Marcos-Gragera R; Gutiérrez-Ávila G; Quirós-García JR; Almela-Vich F; López de Munain A; Sánchez MJ; Franch-Sureda P; Ardanaz E; Galceran J; Martos C; Salmerón D; Gatta G; Botta L; Cañete A; The Spanish Childhood Cancer Epidemiology Working Group

Abstract

Central nervous system (CNS) neoplasms are highly frequent solid tumours in children and adolescents. While some studies have shown a rise in their incidence in Europe, others have not. Survival remains limited. We addressed two questions about these tumours in Spain: (1) Is incidence increasing? and (2) Has survival improved?This population-based study included 1635 children and 328 adolescents from 11 population-based cancer registries with International Classification of Childhood Cancer Group III tumours, incident in 1983-2007. Age-specific and age-standardised (world population) incidence rates (ASRws) were calculated. Incidence time trends were characterised using annual percent change (APC) obtained with Joinpoint. Cases from 1991 to 2005 (1171) were included in Kaplan-Meier survival analyses, and the results were evaluated with log-rank and log-rank for trend tests. Children's survival was age-standardised using: (1) the age distribution of cases and the corresponding trends assessed with Joinpoint; and (2) European weights for comparison with Europe.ASRw 1983-2007: children: 32.7 cases/106; adolescents: 23.5 cases/106. The overall incidence of all tumours increased across 1983-2007 in children and adolescents. Considering change points, the APCs were: (1) children: 1983-1993, 4.3%^ (1.1; 7.7); 1993-2007, -0.2% (-1.9; 1.6); (2) adolescents: 1983-2004: 2.9%^ (0.9; 4.9); 2004-2007: -7.7% (-40; 41.9). For malignant tumours, the trends were not significant. 5-year survival was 65% (1991-2005), with no significant trends (except for non-malignant tumours).CNS tumour incidence in Spain was found to be similar to that in Europe. Rises in incidence may be mostly attributable to changes in the registration of non-malignant tumours. The overall malignant CNS tumour trend

Published
2023

18. Physical and biological properties of electrospun poly(d,l‐lactide)/nanoclay and poly(d,l‐lactide)/nanosilica nanofibrous scaffold for bone tissue engineering

Author

Lopresti F., Pavia F. C., Ceraulo M., Capuana E., Brucato V., Ghersi G., Botta L., La Carrubba V., Lopresti F., Pavia F.C., Ceraulo M., Capuana E., Brucato V., Ghersi G., Botta L., and La Carrubba V.

Subjects
Settore ING-IND/24 - Principi Di Ingegneria Chimica, Tissue Engineering, Tissue Scaffolds, Polyesters, technology, industry, and agriculture, Nanofibers, Settore ING-IND/34 - Bioingegneria Industriale, nanosilica, pre‐osteoblastic cells, Bone and Bones, Cell Line, Nanocomposites, nanoclay, Mice, Settore ING-IND/22 - Scienza E Tecnologia Dei Materiali, Osteogenesis, pre-osteoblastic cells, Animals, polylactic acid, Research Articles, electrospinning, Research Article
Abstract

Electrospun scaffolds exhibiting high physical performances with the ability to support cell attachment and proliferation are attracting more and more scientific interest for tissue engineering applications. The inclusion of inorganic nanoparticles such as nanosilica and nanoclay into electrospun biopolymeric matrices can meet these challenging requirements. The silica and clay incorporation into polymeric nanofibers has been reported to enhance and improve the mechanical properties as well as the osteogenic properties of the scaffolds. In this work, for the first time, the physical and biological properties of polylactic acid (PLA) electrospun mats filled with different concentrations of nanosilica and nanoclay were evaluated and compared. The inclusion of the particles was evaluated through morphological investigations and Fourier transform infrared spectroscopy. The morphology of nanofibers was differently affected by the amount and kind of fillers and it was correlated to the viscosity of the polymeric suspensions. The wettability of the scaffolds, evaluated through wet contact angle measurements, slightly increased for both the nanocomposites. The crystallinity of the systems was investigated by differential scanning calorimetry highlighting the nucleating action of both nanosilica and nanoclay on PLA. Scaffolds were mechanically characterized with tensile tests to evaluate the reinforcing action of the fillers. Finally, cell culture assays with pre‐osteoblastic cells were conducted on a selected composite scaffold in order to compare the cell proliferation and morphology with that of neat PLA scaffolds. Based on the results, we can convince that nanosilica and nanoclay can be both considered great potential fillers for electrospun systems engineered for bone tissue regeneration.

Published
2021

20. 224O Survival differences between EU and Asia for head and neck cancer: Results of the RARECAREnet-Asia collaboration

Author

Trama, A., primary, Matsuda, T., additional, Charvat, H., additional, Chiang, R.R.C-J., additional, van Gestel, A.J., additional, Martin, F., additional, Geleijnse, G., additional, Bonfarnuzzo, S., additional, Licitra, L.F., additional, Cavalieri, S., additional, Resteghini, C., additional, Gatta, G., additional, and Botta, L., additional

Published
2022
Full Text
View/download PDF

21. BIODEGRADABLE POLYMER-BASED COMPOSITES FILLED WITH BIOCHAR FOR TUNABLE RELEASE OF CARVACROL

Author

Botta L., Lopresti F., Pernice G., Garofalo G., Gaglio R., Botta L., Lopresti F., Pernice G., Garofalo G., and Gaglio R.

Subjects
carvacrol, PBAT, biochar, bio-composite
Abstract

Bio-composites are commonly obtained by combining biodegradable polymers with fillers collected from natural resources. In this context, biochar (BC) is attracting high interest as filler for polymer-based composites due to its challenging properties, including ecosustainability. This study aimed to prepare and characterize bio-composites with antimicrobial properties evaluating the role of the filler in the release kinetics. In particular, BC as filler and carvacrol (CRV) as antimicrobial agent, were incorporated via melt-compounding in poly(butylene adipate-co-terephthalate) (PBAT) samples. The rheological, tensile, and antimicrobial properties of the obtained bio-composites were evaluated paying particular attention to the influence of BC concentration, i.e., 5, 10, and 20 wt%, on the investigated properties. Moreover, the influence of BC content on the release kinetics of carvacrol was studied and mathematically modeled to evaluate the release mechanism. The results showed that the presence of biochar modified the carvacrol release in comparison with the unfilled system thus allowing to tune the release kinetics.

Published
2022

22. LEMONGRASS PLANT LEAF AND CULM AS POTENTIAL SOURCES OF REINFORCEMENT FOR BIO-COMPOSITES

Author

Fiore V., Botta L., Pirrone R., Siengchin S., Rangappa S. M., Fiore V., Botta L., Pirrone R., Siengchin S., and Rangappa S.M.

Subjects
Settore ING-INF/05 - Sistemi Di Elaborazione Delle Informazioni, Settore ING-IND/22 - Scienza E Tecnologia Dei Materiali, bio-composites, biodegradable polymers, lemongrass, natural fibers
Abstract

A possible source of natural reinforcement for bio-composites can be represented by lemongrass plant (Cymbopogon flexuosus), a clumped and perennial grass which belongs to the Poaceae family. This plant is extensively used for several applications such as pharmacology, food preservation and cosmetics but, to the best of our knowledge, few papers were published on its use as source for reinforcement of composites and no one article was focused on the comparison between lemongrass leaves and culms as potential source of natural reinforcement. To this aim, a preliminary investigation on leaf and culm fibers was carried out to compare their physical and chemical features as well as their tensile properties. Furthermore, bio-composites based on a biodegradable starch-derived matrix (MaterBi®) and lemongrass leaf and culm particles were manufactured via extrusion and compression molding. For both fillers, two compositions (i.e., 10% and 20 wt.%) were investigated in terms of morphological and mechanical properties.

Published
2022

23. MECHANICAL, RHEOLOGICAL AND THERMAL EVALUATION OF POLY(LACTIC ACID) (PLA)/MICRO FIBRILLATED CELLULOSE (MFC) PLASTICIZED BIOCOMPOSITES PRODUCED WITH FLAT DIE EXTRUSION AND CALENDERING

Author

Gigante V., Aliotta L., Molinari G., D'Ambrosio R., Coltelli M. B., Botta L., La Mantia F. P., Lazzeri A., Gigante V., Aliotta L., Molinari G., D'Ambrosio R., Coltelli M.B., Botta L., La Mantia F.P., and Lazzeri A.

Subjects
biocomposite, Settore ING-IND/22 - Scienza E Tecnologia Dei Materiali, Extrusion, PLA, Cellulose, Migration
Abstract

The use of Micro Fibrillated Cellulose (MFC) as filler for polymeric matrices attempts an increasing interest both in academia and industry. In this framework, encouraging results have been obtained using plasticizers, as dispersing aids, during twin-screw extrusion that optimizes the process parameters and avoid MFC agglomeration. In this work, two commercial typologies of waterborne solution of MFC (Exilva and Celish) were melt-compounded in a PLA matrix through semi-industrial twin-screw extruder and calendered, producing films of 150 μm thickness. These films were mechanically and thermally characterized, moreover the migration of the plasticizer along the time was evaluated through analytical model and the diffusion coefficient was calculated.

Published
2022

26. Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials

Author

Vener, C., Rossi, S., Minicozzi, P., Marcos-Gragera, R., Poirel, H. A., Maynadie, M., Troussard, X., Pravettoni, G., De Angelis, R., Sant, M., Hackl, M., Van Eycken, E., Valerianova, Z., Sekerija, M., Pavlou, P., Dusek, L., Storm, H., Magi, M., Innos, K., Malila, N., Pitkaniemi, J., Velten, M., Bouvier, A. M., Jooste, V., Guizard, A. V., Launoy, G., Yonli, S. D., Woronoff, A. S., Nousbaum, J. B., Coureau, G., Monnereau, A., Baldi, I., Hammas, K., Tretarre, B., Colonna, M., Plouvier, S., D'Almeida, T., Molinie, F., Cowppli-Bony, A., Bara, S., Schvartz, C., Defossez, G., Lapotre-Ledoux, B., Grosclaude, P., Luttmann, S., Stabenow, R., Nennecke, A., Kieschke, J., Zeissig, S., Holleczek, B., Katalinic, A., Birgisson, H., Murray, D., Walsh, P. M., Mazzoleni, G., Vittadello, F., Cuccaro, F., Galasso, R., Sampietro, G., Rosso, S., Magoni, M., Ferrante, M., Sardo, A. S., Gambino, M. L., Ballotari, P., Giacomazzi, E., Ferretti, S., Caldarella, A., Manneschi, G., Gatta, G., Baili, P., Berrino, F., Botta, L., Trama, A., Lillini, R., Bernasconi, A., Bonfarnuzzo, S., Didone, F., Lasalvia, P., Del Monego, G., Magri, M. C., Buratti, L., Serraino, D., Dal Maso, L., Capocaccia, R., Demuru, E., Di Benedetto, C., Santaquilani, M., Venanzi, S., Filiberti, R. A., Iacovacci, S., Gennaro, V., Russo, A. G., Spagnoli, G., D'Oro, L. C., Fusco, M., Vitale, M. F., Usala, M., Vitale, F., Michiara, M., Chiranda, G., Cascone, G., Spata, E., Mangone, L., Falcini, F., Cavallo, R., Piras, D., Madeddu, A., Bella, F., Fanetti, A. C., Minerba, S., Candela, G., Scuderi, T., Rizzello, R. V., Stracci, F., Tagliabue, G., Rugge, M., Brustolin, A., Pildava, S., Smailyte, G., Azzopardi, M., Johannesen, T. B., Didkowska, J., Wojciechowska, U., Bielska-Lasota, M., Pais, A., Pontes, J. L., Miranda, A., Diba, C. S., Zadnik, V., Zagar, T., Escudero, C. S. -C., Sureda, P. F., de Munain, A. L., De-La-cruz, M., Rojas, M. D., Aleman, A., Vizcaino, A., Sanchez, M. J., Chirlaque, M. D., Eslava, M. G., Ardanaz, E., Galceran, J., Carulla, M., Bergeron, Y., Bouchardy, C., Mousavi, S. M., Bordoni, A., Visser, O., Rashbass, J., Gavin, A., Morrison, D., and Huws, D. W.

Subjects
Cancer Research, Survival, real-world data, randomized controlled trials (RCTs), tyrosine kinase inhibitor (TKI), population-based studies, Tyrosine kinase inhibitor (TKI), Randomized controlled trials (RCTs), survival, Real-world data, Europe, Oncology, cancer registries, chronic myeloid leukemia (CML), Chronic myeloid leukemia (CML), Cancer registries, Population-based studies
Abstract

This study was funded by the Compagnia di San Paolo, the Cariplo Foundation and the European Commission (grant number 801520 HP-JA-2017, Innovative Partnership for Action Against Cancer, iPAAC Joint Action). The sources of the funding played no role in designing the study, collecting, analyzing, or interpreting the data, writing the report, or deciding whether or not to submit the article for publication. This research was (partially) funded by Italian Ministry of Health "Ricerca Corrente" funds. Tyrosine kinase inhibitors (TKIs) have been improving the prognosis of patients with chronic myeloid leukemia (CML), but there are still large differences in survival among European countries. This raises questions on the added value of results from population-based studies, which use real-world data, compared to results of randomized controlled trials (RCTs) involving patients with CML. There are also questions about the extent of the findings on RCTs effectiveness for patients in the general population. We compare survival data extracted from our previous systematic review and meta-analysis of CML RCTs with the latest updated population-based survival data of EUROCARE-6, the widest collaborative study on cancer survival in Europe. The EUROCARE-6 CML survival estimated in patients (15-64 years) diagnosed in 2000-2006 vs. 2007-2013 revealed that the prognostic improvement highlighted by RCTs was confirmed in real-world settings, too. The study shows, evaluating for the first time all European regions, that the optimal outcome figures obtained in controlled settings for CML are also achievable (and indeed achieved) in real-world settings with prompt introduction of TKIs in daily clinical practice. However, some differences still persist, particularly in Eastern European countries, where overall survival values are lower than elsewhere, probably due to a delayed introduction of TKIs. Our results suggest an insufficient adoption of adequate protocols in daily clinical practice in those countries where CML survival values remain lower in real life than the values obtained in RCTs. New high-resolution population-based studies may help to identify failures in the clinical pathways followed there.

Published
2022

29. Erratum: The Italian national project of astrobiology-life in space-origin, presence, persistence of life in space, from molecules to extremophiles (Astrobiology (2020) 20:5 (580-582) DOI: 10.1089/ast.2020.2247)

Author

Onofri S., Balucani N., Barone V., Benedetti P., Billi D., Balbi A., Brucato J. R., Cobucci-Ponzano B., Costanzo G., Rocca N. L., Moracci M., Saladino R., Vladilo G., Albertini N., Battistuzzi M., Bloino J., Botta L., Casavecchia P., Cassaro A., Claudi R., Cocola L., Coduti A., Di Donato P., Di Mauro E., Dore L., Falcinelli S., Fulle M., Ivanovski S., Lombardi A., Mancini G., Maris M., Maurelli L., Murante G., Negri R., Pacelli C., Pagano I., Piccinino D., Poletto L., Prantera G., Puzzarini C., Rampino S., Ripa C., Rosi M., Sanna M., Selbmann L., Silva L., Skouteris D., Strazzulli A., Tasinato N., Timperio A. M., Tozzi A., Tozzi G. P., Trainotti L., Ugliengo P., Vaccaro L., Zucconi L., Onofri S., Balucani N., Barone V., Benedetti P., Billi D., Balbi A., Brucato J.R., Cobucci-Ponzano B., Costanzo G., Rocca N.L., Moracci M., Saladino R., Vladilo G., Albertini N., Battistuzzi M., Bloino J., Botta L., Casavecchia P., Cassaro A., Claudi R., Cocola L., Coduti A., Di Donato P., Di Mauro E., Dore L., Falcinelli S., Fulle M., Ivanovski S., Lombardi A., Mancini G., Maris M., Maurelli L., Murante G., Negri R., Pacelli C., Pagano I., Piccinino D., Poletto L., Prantera G., Puzzarini C., Rampino S., Ripa C., Rosi M., Sanna M., Selbmann L., Silva L., Skouteris D., Strazzulli A., Tasinato N., Timperio A.M., Tozzi A., Tozzi G.P., Trainotti L., Ugliengo P., Vaccaro L., Zucconi L., Onofri, S., Balucani, N., Barone, V., Benedetti, P., Billi, D., Balbi, A., Brucato, J. R., Cobucci-Ponzano, B., Costanzo, G., Rocca, N. L., Moracci, M., Saladino, R., Vladilo, G., Albertini, N., Battistuzzi, M., Bloino, J., Botta, L., Casavecchia, P., Cassaro, A., Claudi, R., Cocola, L., Coduti, A., Di Donato, P., Di Mauro, E., Dore, L., Falcinelli, S., Fulle, M., Ivanovski, S., Lombardi, A., Mancini, G., Maris, M., Maurelli, L., Murante, G., Negri, R., Pacelli, C., Pagano, I., Piccinino, D., Poletto, L., Prantera, G., Puzzarini, C., Rampino, S., Ripa, C., Rosi, M., Sanna, M., Selbmann, L., Silva, L., Skouteris, D., Strazzulli, A., Tasinato, N., Timperio, A. M., Tozzi, A., Tozzi, G. P., Trainotti, L., Ugliengo, P., Vaccaro, L., and Zucconi, L.

Subjects
life in space-origin, astrobiology, persistence of life in space, from molecules to extremophiles in space, Settore CHIM/02 - Chimica Fisica
Abstract

The Italian National Project of Astrobiology―Life in Space―Origin, Presence, Persistence of Life in Space, from Molecules to Extremophiles A member’s name should be added to the OPPS Project Team: Stavro Ivanovski on page 580 footnotes. We have made this correction on the title page of the article and the eTOC.

Published
2020

30. Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort

Author

Trama, A, Tittarelli, A, Barigelletti, G, Botta, L, Gatta, G, Tagliabue, G, Contiero, P, Guzzinati, S, Andreano, A, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Mazzucco, W, Mangone, L, Iacovacci, S, Vitale, M, Stracci, F, Piffer, S, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Ballotari, P, Boschetti, L, Pisani, S, Cavalieri D'Oro, L, Cuccaro, F, D'Argenzio, A, D'Orsi, G, Fanetti, A, Ardizzone, A, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Bernasconi, A, Trama, Annalisa, Tittarelli, Andrea, Barigelletti, Giulio, Botta, Laura, Gatta, Gemma, Tagliabue, Giovanna, Contiero, Paolo, Guzzinati, Stefano, Andreano, Anita, Manneschi, Gianfranco, Falcini, Fabio, Castaing, Marine, Filiberti, Rosa A, Gasparotti, Cinzia, Cirilli, Claudia, Mazzucco, Walter, Mangone, Lucia, Iacovacci, Silvia, Vitale, Maria F, Stracci, Fabrizio, Piffer, Silvano, Tumino, Rosario, Carone, Simona, Sampietro, Giuseppe, Melcarne, Anna, Ballotari, Paola, Boschetti, Lorenza, Pisani, Salvatore, Cavalieri D'Oro, Luca, Cuccaro, Francesco, D'Argenzio, Angelo, D'Orsi, Giancarlo, Fanetti, Anna C, Ardizzone, Antonino, Candela, Giuseppa, Savoia, Fabio, Pascucci, Cristiana, Castelli, Maurizio, Storchi, Cinzia, Bernasconi, Alice, Trama, A, Tittarelli, A, Barigelletti, G, Botta, L, Gatta, G, Tagliabue, G, Contiero, P, Guzzinati, S, Andreano, A, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Mazzucco, W, Mangone, L, Iacovacci, S, Vitale, M, Stracci, F, Piffer, S, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Ballotari, P, Boschetti, L, Pisani, S, Cavalieri D'Oro, L, Cuccaro, F, D'Argenzio, A, D'Orsi, G, Fanetti, A, Ardizzone, A, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Bernasconi, A, Trama, Annalisa, Tittarelli, Andrea, Barigelletti, Giulio, Botta, Laura, Gatta, Gemma, Tagliabue, Giovanna, Contiero, Paolo, Guzzinati, Stefano, Andreano, Anita, Manneschi, Gianfranco, Falcini, Fabio, Castaing, Marine, Filiberti, Rosa A, Gasparotti, Cinzia, Cirilli, Claudia, Mazzucco, Walter, Mangone, Lucia, Iacovacci, Silvia, Vitale, Maria F, Stracci, Fabrizio, Piffer, Silvano, Tumino, Rosario, Carone, Simona, Sampietro, Giuseppe, Melcarne, Anna, Ballotari, Paola, Boschetti, Lorenza, Pisani, Salvatore, Cavalieri D'Oro, Luca, Cuccaro, Francesco, D'Argenzio, Angelo, D'Orsi, Giancarlo, Fanetti, Anna C, Ardizzone, Antonino, Candela, Giuseppa, Savoia, Fabio, Pascucci, Cristiana, Castelli, Maurizio, Storchi, Cinzia, and Bernasconi, Alice

Abstract

Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 AYA cancer survivors. The excess risk of developing any SMN (SIR, 1.6; 95% confidence interval, 1.5-1.7) was 60%. The excess risk of SMNs was significantly high for survivors of lymphomas; cancers of the breast, thyroid, female genital tract, digestive organs, gonads, and urinary tract; and melanomas. The cumulative incidence of all SMNs in AYA cancer survivors within 25 years of their first cancer diagnosis was approximately 10%. Subsequent tumors contributing to approximately 60% of all SMNs were breast cancer, colorectal cancer, corpus uteri cancer, and ovarian cancer in females and colorectal cancer, bladder cancer, prostate cancer, lung cancer, and lymphomas in males. Conclusions: These results highlight the need to personalize follow-up strategies for AYA cancer survivors.

Published
2022

31. COVID-19 outbreak in Lombardy: Impact on reducing solid cancer diagnoses in 2020

Author

Trama, A, Bernasconi, A, Botta, L, Di Cosimo, S, Miceli, R, Claps, M, Badenchini, F, Lillini, R, Rubino, M, Lasalvia, P, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Di Cosimo, Serena, Miceli, Rosalba, Claps, Melanie, Badenchini, Fabio, Lillini, Roberto, Rubino, Massimiliano, Lasalvia, Paolo, Trama, A, Bernasconi, A, Botta, L, Di Cosimo, S, Miceli, R, Claps, M, Badenchini, F, Lillini, R, Rubino, M, Lasalvia, P, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Di Cosimo, Serena, Miceli, Rosalba, Claps, Melanie, Badenchini, Fabio, Lillini, Roberto, Rubino, Massimiliano, and Lasalvia, Paolo

Abstract

Our aim was to analyse, on a population level, the year-long decline in cancer diagnoses in the region of Lombardy (Italy), and to characterise the tumours with the greatest reduction in diagnosis by patient age, sex and tumour stage at diagnosis. We used the health care utilisation databases of the Lombardy region to identify cancer patients' characteristics (eg, sex, age) and cancer-related information (eg, cancer site, stage at diagnosis). The frequency of new cancer diagnoses in 2019 and 2020 were compared in terms of percentage differences in undiagnosed cases. We observed two peaks in the decline in cancer diagnoses: March to May 2020 (−37%) and October to December 2020 (−19%). The decline persisted over the course of 2020 and was higher in males and patients aged 74+. Diagnoses of all four common cancers analysed (female breast, lung, colorectal and prostate) remained below pre-pandemic levels. For breast and colorectal cancers, the decline in diagnoses was high in the age groups targeted by population-based screening programmes. We observed a reduction in localised stage cancer diagnoses for all four cancers. Our data confirm that timely monitoring of cancer diagnoses and interventions to prevent disruption of routine diagnostic services are needed to mitigate the impact of emergencies on cancer patients.

Published
2022

32. Late mortality reduction among survivors of germ cell tumors in childhood and adolescence in Europe: A report from the PanCareSurFup cohort

Author

Trama, A, Bernasconi, A, Botta, L, Byrne, J, Grabow, D, Reulen, R, Calaminus, G, Terenziani, M, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C, Calaminus, Gabriele, Terenziani, Monica, Trama, A, Bernasconi, A, Botta, L, Byrne, J, Grabow, D, Reulen, R, Calaminus, G, Terenziani, M, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C, Calaminus, Gabriele, and Terenziani, Monica

Abstract

Background: Data on late mortality from pediatric germ cell tumors (GCTs) are limited to small case series. Our population-based study aimed to investigate excess risk of death in survivors of GCT in childhood and adolescence, whether long-term mortality changed over time and by period of diagnosis. Methods: The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 2773 five-year survivors diagnosed under 21 years of age with gonadal and extragonadal GCT (from 1940 to 2008). We calculated standardized mortality ratios (SMRs) and absolute excess risks (AERs). We fitted a Cox's model to assess the impact of treatment period. We estimated 10-year survival and calculated average percentage changes between periods of diagnosis (1970–1979, 1980–1989, 1990–1999) to assess whether late mortality decreased. Results: GCT survivors had an almost four-fold excess risk of dying compared to general population. The risk of death for patients treated after 1980 was nearly halved compared to patients treated before 1980. Survivors diagnosed in 1990–1999 had a 10-year survival rate of 99%, which was 2.4% and 1.1% higher than for patients treated in 1970–1979 and 1980–1989, respectively. Conclusions: This is the largest population-based study in Europe and showed a decrease in long-term mortality for survivors of GCTs in childhood and adolescence over the last decades. After the introduction of platinum compound in 1980, which is a paradigm of success compared to the previous treatments, no major changes in drug therapies have been made to treat GCTs in the last 40 years. However, GCT survivors maintain an excessive risk of death that requires long-term care.

Published
2022

38. Medium-Long Term Results of Cardiac Transplantation from Donors Assessed with the “Aged Donor Heart Rescue by Stress Echo” (ADONHERS) Protocol

Author

Suarez, S. Martin, primary, Fiorentino, M., additional, Murana, G., additional, Botta, L., additional, Loforte, A., additional, Santamaria, V., additional, Pagano, V., additional, Prestinenzi, P., additional, Sabatino, M., additional, Bombardini, A., additional, Sangiorgi, G., additional, Potena, L., additional, and Pacini, D., additional

Published
2022
Full Text
View/download PDF

40. Design for social innovations: a proposal for an holistic design approach

Author

Bisson, M., Palmieri, S., Ianniello, A., Palomba, R., and Botta, L.

Subjects
New Relationships, Sustainable communities, Social innovation, Transition product design, Holistic approach, Transition product design, Sustainable communities, Social innovation, New Relationships, Holistic approach
Published
2022

44. Comparison of different processing methods to prepare poly(lactid acid)-hydrotalcite composites

Author

Scaffaro, R., Botta, L., Passaglia, E., Oberhauser, W., Frediani, M., and Di Landro, L.

Subjects
Lactic acid -- Usage, Polymeric composites -- Production processes -- Comparative analysis, Engineering and manufacturing industries, Science and technology
Abstract

The effect of the compounding method on the morphology and on the properties of poly(lactic acid) (PLA)-hydrotalcite (HT) composites was studied. Moreover, the influence of two different kinds of HT--organically modified (OM-HT) and unmodified (U-HT)--and their concentration was evaluated. The composites were prepared using either a single screw extruder (SSE), a counter rotating twin-screw compounder (TSC) or a corotating twin-screw extruder (TSE). The prepared materials were characterized by scanning electron microscopy, gel permeation chromatography (GPC) analysis, mechanical and rheological measurements. The results indicated that the best morphology, i.e., particles dimension and distribution, is exhibited by materials prepared by TSE while the worse ones by the samples processed by SSE. The viscosity of all the materials containing the HT is lower in comparison with the viscosity exhibited by the neat matrix, in particular, when the OM-HT is used. These results were correlated to degradation phenomena occurring during the processing of the materials as revealed by the results of GPC analysis. The addition of HT caused only a slight increase of elastic modulus of filled materials even when 5% of filler was incorporated. However, in full agreement with morphological analyses, the best performances were exhibited by materials prepared by TSE while the worse ones by the samples processed by SSE., INTRODUCTION Over the past decades there has been a growing interest toward polymeric materials obtained by renewable sources and with potential biodegradability or compost-ability to reduce the overall environmental impact [...]

Published
2014
Full Text
View/download PDF

48. Changes in life expectancy for cancer patients over time since diagnosis

Author

Botta, L., Dal Maso, L., Guzzinati, S., Panato, C., Gatta, G., Trama, A., Rugge, M., Tagliabue, G., Casella, C., Caruso, B., Michiara, M., Ferretti, S., Sensi, F., Tumino, R., Toffolutti, F., Russo, A. G., Caiazzo, A. L., Mangone, L., Mazzucco, W., Iacovacci, S., Ricci, P., Gola, G., Candela, G., Sardo, A. S., De Angelis, R., Buzzoni, C., Capocaccia, R., AIRTUM Working Group, Botta, Laura, Dal Maso, Luigino, Guzzinati, Stefano, Panato, Chiara, Gatta, Gemma, Trama, Annalisa, Rugge, Massimo, Tagliabue, Giovanna, Casella, Claudia, Caruso, Bianca, Michiara, Maria, Ferretti, Stefano, Sensi, Flavio, Tumino, Rosario, Toffolutti, Federica, Giampiero Russo, Antonio, Luisa Caiazzo, Anna, Mangone, Lucia, Mazzucco, Walter, Iacovacci, Silvia, Ricci, Paolo, Gola, Gemma, Candela, Giuseppa, Sutera Sardo, Antonella, De Angelis, Roberta, Buzzoni, Carlotta, and Capocaccia, Riccardo

Subjects
0301 basic medicine, Pediatrics, medicine.medical_specialty, cancer survivor, Life expectancy, Cancer survivors, Population, YLL, years of life lost, (ICD-O-3), international classification of diseases for oncology, third revision, Socio-culturale, Life expectancy, Population-based cancer registry, Relative survival, Cancer, Cancer survivors, Italy, Settore MED/42 - Igiene Generale E Applicata, Relative survival, 03 medical and health sciences, 0302 clinical medicine, Health care, Medicine, education, lcsh:Science (General), Population-based cancer registry, Thyroid cancer, Cancer, RS, relative survival, education.field_of_study, lcsh:R5-920, Multidisciplinary, business.industry, Absolute risk reduction, medicine.disease, LE, life expectancy, NHL, non-Hodgkin lymphoma, 030104 developmental biology, Years of potential life lost, Italy, ISTAT, national institute of statistics, 030220 oncology & carcinogenesis, (ICD-10), international classification of diseases tenth revision, Original Article, business, lcsh:Medicine (General), lcsh:Q1-390
Abstract

Highlights • Research question: how cancer impacts on LE changes during patients’ entire life • LE increased in patients surviving the first years and decreasing thereafter. • Patients’ LE in the end approached but seldom reached the general population’s LE. • This method describes when cancer survivors’ excess risk of death became negligible. • Life expectancy indicator is easy to be understood and interpreted by patients., Graphical abstract, The aims of this study were to provide life expectancy (LE) estimates of cancer patients at diagnosis and LE changes over time since diagnosis to describe the impact of cancer during patients' entire lives. Cancer patients' LE was calculated by standard period life table methodology using the relative survival of Italian patients diagnosed in population-based cancer registries in 1985–2011 with follow-up to 2013. Data were smoothed using a polynomial model and years of life lost (YLL) were calculated as the difference between patients' LE and that of the age- and sex-matched general population. The YLL at diagnosis was highest at the youngest age at diagnosis, steadily decreasing thereafter. For patients diagnosed at age 45 years, the YLL was above 20 for lung and ovarian cancers and below 6 for thyroid cancer in women and melanoma in men. LE progressively increased in patients surviving the first years, decreasing thereafter, to approach that of the general population. YLL in the long run mainly depends on attained age. Providing quantitative data is essential to better define clinical follow-up and plan health care resource allocation. These results help assess when the excess risk of death from tumour becomes negligible in cancer survivors.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results